Veradermics Prices Upsized IPO at $17, Expected to Raise $256.3M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Should l Buy ?
Source: seekingalpha
- IPO Pricing and Size: Veradermics has priced its upsized IPO at $17 per share, offering 15,077,647 shares, which is expected to raise approximately $256.3 million in gross proceeds before fees and expenses, indicating strong market demand for its product.
- Market Valuation: At the IPO price, Veradermics is valued at around $596 million, reflecting investor confidence in its non-hormonal hair loss treatment VDPHL01, which may provide funding for future research and development.
- Investor Interest: Wellington Management expressed interest in purchasing up to $30 million of shares at the IPO price, while Eli Lilly indicated it could acquire up to 4.9% of the biotech's outstanding shares, showcasing significant attention from large investors.
- Trading Arrangement: The stock is set to begin trading on the New York Stock Exchange on February 4, 2026, with underwriters having a 30-day option to buy an additional 2,261,647 shares, further enhancing market liquidity and investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
